ArticleLeukemia2026

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

Carsten U Niemann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.